@CapitalZone: Boon for Retail Traders - Currency Option

@StickyRice:Novo Nordisk to sell Wegovy in bigger European markets -- Bloomberg Novo Nordisk $Novo-Nordisk A/S(NVO)$ has resolved production issues that impacted availability of its hugely popular weight loss drug Wegovy (semaglutide) and now says it will launch the drug in larger European markets later this year. Speaking on Bloomberg Television's "Bloomberg Markets," CEO Lars Fruergaard Jorgensen didn't discuss where exactly those markets might be. He noted that currently, the drug is available in Norway and Denmark, though patients have to pay out of pocket. He said he is hopeful that discussions with many European markets that cover Novo's (NVO) older obesity drug, Saxenda (liraglutide), will lead to them also reimbursing Wegovy. Jorgensen added that

@Keeley:$Grab Holdings(GRAB)$ #GRAB Price did not play out as analyzed last week, price took out buy-side liquidity and proceeded to take external liquidity at 4.00 before heading lower. Right now, the probability of price taking sell-side liquidity is increased and potential target for this down move is the main bullish POI at 2.49. https://www.tradingview.com/chart/GRAB/S4Kf8Fv2-GRAB-Analysis/